Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GREM1 Deficiency induced Bone Marrow Adipose Niche promotes B-cell Acute Lymphoblastic Leukemia Disease Progression

ABSTRACT: Relapse and disease progression are the primary causes of treatment failure and subsequent mortality in children B-cell acute lymphocytic leukemia (B-ALL). At diagnosis and during treatment, the bone marrow adipose microenvironment is commonly observed in pediatric leukemia. However, the relationship between the bone marrow adipose microenvironment and disease progression is still not well understood.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS10103 | MetaboLights | 2024-09-23

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	C18-NEG-IDA-01.wiff	Wiff
	C18-NEG-IDA-01.wiff.scan	Wiff
	C18-NEG-IDA-03.wiff	Wiff
	C18-NEG-IDA-03.wiff.scan	Wiff
	C18-NEG-IDA-05.wiff	Wiff

Items per page:

1 - 5 of 217

Similar Datasets

The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution

Project description:The bone marrow microenvironment of leukemia plays a key role in leukemia progression, but its molecular complexity in pre-B acute lymphoblastic leukemia (B-ALL), the most common cancer in children, remains poorly understood. Here we use single-cell RNA sequencing to characterise the bone marrow microenvironment during B-ALL progression.

2020-07-27 | GSE148115 | GEO

The effect of bcCML leukemia progression on the bone marrow microenvironment

Project description:The effect of bcCML leukemia progression on the bone marrow microenvironment

| PRJNA940987 | ENA

Leukemia-on-a-Chip: Dissecting the chemo-resistance mechanisms in B-cell acute lymphoblastic leukemia (B-ALL) bone marrow niche

Project description:B-cell acute lymphoblastic leukemia (B-ALL) blasts hijack the bone marrow (BM) microenvironment to form chemo-protective leukemic BM ‘niches’, facilitating chemo-resistance and, ultimately, disease relapse. However, the ability to dissect these evolving, complex interactions among distinct B-ALL subtypes and their varying BM niches is limited with current in vivo methods. Herein, we reconstituted an in vitro three-dimensional (3D) organotypic leukemic BM niche model using a ‘Leukemia-on-a-Chip’ platform and comparatively studied the spatial and genetic heterogeneity of the BM niche in regulating B-ALL chemotherapy resistance. By emulating the leukemia BM anatomy in vitro, we determined that the perivascular and endosteal niches, through providing cytokine (e.g. CXCL12) and adhesive (e.g. VCAM-1/OPN) signals, differentially enhance downstream leukemia-intrinsic NF-κB signaling to support B-ALL survival and regulate cell cycle-related signaling to promote dormancy, which following demonstrated the pre-clinical utility of this microphysiological system to screen concomitant niche-directed therapies. Furthermore, we revealed the heterogeneity across different B-ALL subtypes by mapping subtype-specific leukemia and niche signals with application of single-cell RNA sequencing and analysis, which may contribute to chemotherapy resistance and disease relapse. Together, these results validate that our Leukemia-on-a-Chip allows for real-time and controllable dissection of the dynamic and heterotypic interactions between leukemia blasts and their BM microenvironment, which may translate to personalized therapeutics screening and disease management.

2020-10-31 | GSE138811 | GEO

Cell-cell interactome of the hematopoietic niche and its changes in acute myeloid leukemia

Project description:Acute myeloid leukemia (AML) is an aggressive cancer which causes the rapid proliferation of immature myeloid-lineage blood cells (myeloblasts) in the bone marrow. These leukemic cells receive trophic signals from the bone marrow micro-environment (BMM) in which they reside, that are essential to the initiation and maintenance of the disease. Because this is a complex and heterogeneous tissue, many aspects of this environment remain poorly characterised due to experimental hurdles. Here we performed single-cell RNA-sequencing of bone marrow aspirates from 10 AML patients across multiple key timepoints in disease progression (diagnosis, post-treatment, relapse).

2023-06-13 | GSE227903 | GEO

Proteomics of mouse bone marrow MLL-AF9 leukemia cells treated with Lep or Allo-aca in combination with Arac

Project description:Leptin is enriched in bone marrow adipose tissue, but its impact on therapeutic response in acute myeloid leukemia (AML) remains incompletely elucidated. Here, we report that in MLL-AF9 mouse model, exogenous leptin significantly compromised the cytotoxicity of Ara-C, whereas a high-affinity leptin receptor antagonist, Allo-aca, restored chemosensitivity without altering basal leukemia growth, accompanied by marked alterations in mitochondria-associated proteins.

2025-07-28 | PXD066693 |

TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment

Project description:Chronic myeloid leukemia (CML) cells circulate between blood and bone marrow niche, representing different microenvironments. We studied the role of the two RNA binding proteins, T-cell-restricted intracellular antigen (TIAR) and the fragile X mental retardation protein (FMRP) in the regulation of protein translation in CML cells residing in settings mimicking peripheral blood microenvironment (PBM) and bone marrow microenvironment (BMM). We studied how conditions shaped the translation process through TIAR and FMRP activity, considering its relevance in therapy resistance. The QuaNCAT mass-spectrometric approach revealed that TIAR and FMRP have a discrete modulatory effect on protein synthesis and thus affect distinct aspects of leukemic cells functioning in the hypoxic niche. We demonstrate that TIAR substantially supports the resistance of CML cells to translation inhibition by homoharringtonine in the BMM. Overall, our results show that targeting post-transcriptional control should be considered when designing anti-leukemia therapeutic solutions.

2023-05-10 | PXD032332 | Pride

Investigation of the Altered Transcriptomic Dynamics of Bone Marrow Adipose Tissue Under Exogenous Stimuli in the Context of AML Pathogenesis

Project description:Bone marrow is a critical tissue for hematopoietic stem cell regulation, comprising various cell types, including adipose tissue, which actively contributes to hematopoietic biology. The mechanisms underlying the transcriptomic response of bone marrow adipose tissue to xenobiotic stimuli remain poorly understood, particularly its role in leukemia progression. Acute myeloid leukemia (AML) stromal cells differ significantly from healthy bone marrow stroma, with environmental pollutants and xenobiotics playing a crucial role in pathogenesis. This study investigates the transcriptomic alterations in bone marrow adipose-derived mesenchymal stem cells following aryl hydrocarbon receptor (AhR) agonist and antagonist stimulation. Comparative analyses include healthy donors, Fanconi anemia (FA), and AML samples to elucidate their contributions to leukemia development.

2025-05-22 | GSE283315 | GEO

Bone marrow niche

Project description:Bone marrow niche

| PRJNA429031 | ENA

Single-cell transcriptome landscape suggests novel fingerprint of relapse in acute monocytic leukemia post transplantation

Project description:We analyzed transcriptome data from above 50K single leukemia bone marrow cells across 3 patients during newly diagnosed, complete remission and relapse stages. These 3 patients belong to M4 or M5, according to French-American-British classification. We analyze heterogeneity of acute myeloid leukemia during progression and identify novel relapse subgroups in these heterogeneous populations.

2025-04-17 | GSE201966 | GEO

Bone marrow microenvironment mediated drug resistance in Acute promyelocytic leukemia

Project description:Bone marrow microenvironment mediated drug resistance in Acute promyelocytic leukemia

| PRJNA514741 | ENA